About ProAxsis
ProAxsis is a company based in Belfast (United Kingdom) founded in 2013 by Lorraine Martin and Brian Walker was acquired by NetScientific in October 2020. ProAxsis has raised $2.79 million across 6 funding rounds from investors including European Union, EMV Capital and AB Group. ProAxsis offers products and services including NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology. ProAxsis operates in a competitive market with competitors including Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Eclipse Bio, among others.
- Headquarter Belfast, United Kingdom
- Founders Lorraine Martin, Brian Walker
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Proaxsis Ltd
- Date of Incorporation 16 Aug, 2013
- Jurisdiction BELFAST, NORTHERN IRELAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.79 M (USD)
in 6 rounds
-
Latest Funding Round
$298.56 K (USD), Seed
Jul 07, 2025
-
Investors
European Union
& 3 more
-
Employee Count
Not available
-
Acquired by
NetScientific
(Oct 16, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ProAxsis
ProAxsis offers a comprehensive portfolio of products and services, including NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology.
Detects active neutrophil elastase for respiratory disease diagnostics.
Assay for detecting active proteinase biomarkers in chronic conditions.
Enables protease detection in ELISA and lateral flow devices.
People of ProAxsis
Unlock access to complete
Unlock access to complete
Funding Insights of ProAxsis
ProAxsis has successfully raised a total of $2.79M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $298.56 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ProAxsis
ProAxsis has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EMV Capital and AB Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Venture capital investments are made in deep tech and life sciences by EMV Capital.
|
Locked | Locked | Locked | |
|
AB Group is engaged in managing retail construction and refurbishment projects.
|
Locked | Locked | Locked |
Investor details for ProAxsis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ProAxsis
Investment portfolio details for ProAxsis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ProAxsis
Detailed financials for ProAxsis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Proaxsis Comparisons
Peer comparison for ProAxsis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ProAxsis
ProAxsis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Eclipse Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of immunoassays for diagnostic purposes
|
|
| Locked | Locked | Locked |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| Locked | Locked | Locked |
Provider of products and services for human protein biomarker research and development
|
|
| Locked | Locked | Locked |
An in vitro assay platform is provided for diagnostic solutions.
|
|
| Locked | Locked | Locked |
Cell-free immunoassays are developed to identify RNA binding protein targets.
|
|
| Locked | Locked | Locked |
Correlia Biosystems is focused on protein quantification technology.
|
Detailed competitors of ProAxsis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proaxsis
Complete news archive for ProAxsis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ProAxsis
ProAxsis was founded in 2013 and raised its 1st funding round 1 year after it was founded.
ProAxsis is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.
David Ribeiro is the current CEO of ProAxsis.
ProAxsis is a funded company, having raised a total of $2.79M across 6 funding rounds to date.
ProAxsis was founded in 2013 in Belfast, United Kingdom, within the biotechnology sector. ProteaseTags, an active neutrophil elastase immunoassay, have been developed to bind and quantify the activity of specific proteases in complex biological samples. Services provided include clinical research support, biomarker development, and academic collaborations, with operations focused on diagnostic and research applications in healthcare.
ProAxsis's top competitors include Abingdon Health, Eclipse Bio and Spear Bio.
ProAxsis offers NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology.
ProAxsis has 4 investors. Key investors include European Union, EMV Capital, AB Group, and EIC Fund.